2010

  • Peter George forms the Clinigen Group by bringing together Clinigen, Clinigen Healthcare and Keats Healthcare
  • Clinigen acquires its first product, Foscavir and commences Global Access Programs supplying unlicensed medicines globally
  • Employees: 32

2011

  • Clinigen recognised as the fastest-growing private company in the UK by the Sunday Times Virgin Fast Track 100
  • Employees: 48

2012

  • Clinigen moves warehousing into brand new Operations Centre
  • Clinigen lists on the Alternative Investment Market (AIM) of the London Stock Exchange – the first UK healthcare company to list in London in five years
  • Employees: 72

2013

  • Clinigen marks its first year as a public company by winning Best Newcomer at the London Stock Exchange AIM Awards
  • Clinigen wins IPO of the Year at the 2013 M&A Awards
  • Clinigen SP acquires its second product, Cardioxane
  • Employees: 101

2014

  • Clinigen opens new, extended headquarters in Burton-on-Trent, UK
  • Clinigen acquires its third product, Savene
  • Clinigen acquires its fourth product, Ethyol
  • Peter George wins Chief Executive of the Year at 2014 European Mediscience Awards
  • Clinigen launches its new web portal, Cliniport, which allows healthcare professionals to order products directly via the internet
  • Employees: 116

2015

  • Clinigen acquires Idis in April 2015 to become the global leader in providing ethical compliant access to unlicensed medicines
  • Clinigen acquires Link Healthcare in October 2015 to expand its ability to provide access to medicines for patients in the Africa, Asia and Australia regions
  • Clinigen awarded the ServiceMark accreditation by The Institute of Customer Service, in recognition of the Group’s commitment to, and achievement in, customer services
  • Employees: 450

2016

  • Launch of Japanese business, Clinigen KK, with Foscavir as its first product
  • Clinigen acquires its fifth product, Totect US, completing the global dexrazoxane portfolio
  • Clinigen continues Foscavir development with purchase of a new bag presentation
  • Clinigen launches Ethyol in the US in partnership with Cumberland Pharma
  • Shaun Chilton replaces Peter George as Chief Executive Officer of Clinigen Group plc
  • Employees: 530

2017

  • Clinigen receives investors in people silver award
  • Clinigen receives EC approval for updates to Cardioxane product information
  • Clinigen launched Totect in the US in partnership with Cumberland Pharma
  • Clinigen acquires IMMC, Japan’s largest supplier of unlicensed medicines
  • Clinigen acquires Quantum Pharma plc in November 2017 extending its Unlicensed Medicines capability and accelerating its unlicensed to licensed global strategy
  • Employees: 849

2018

  • Clinigen signs extended partnership agreement with Bristol-Myers Squibb to supply its portfolio of products in South Africa
  • Clinigen acquires its sixth product, Proleukin (global rights outside the US)
  • Clinigen acquires its seventh product, Imukin (global rights outside the US, Canada and Japan)
  • Clinigen acquires CSM a specialist provider of packaging, labelling, warehousing and distribution services with infrastructure in the US, Belgium and Germany
  • Clinigen acquires iQone, a Swiss-based specialty pharmaceutical business providing EU medical scientific liaison (MSL) capability
  • Employees: 1,182

2019

  • Clinigen acquires the US rights to Proleukin
  • Clinigen Direct is a globally available service which helps clinicians, pharmacists and pharmacy technicians source hard to find medicines by connecting them with our specialist customer services team, either online or by phone (and even fax).